{
  "nct_id": "NCT02351479",
  "trial_title": "Hula, a Physical Activity Intervention for Female-Cancer Survivors",
  "patient_id": "ayesha_001",
  "generated_at": "2025-11-14T18:00:10.188110",
  "sections": {
    "1_trial_overview": {
      "title": "Hula, a Physical Activity Intervention for Female-Cancer Survivors",
      "phase": "",
      "status": "COMPLETED",
      "sponsor": "",
      "estimated_enrollment": 0,
      "primary_endpoint": null
    },
    "2_eligibility_assessment": {
      "table": [
        {
          "criterion": "Disease Match",
          "status": "PASS",
          "confidence": 0.9,
          "notes": "Ovarian/gynecologic match: [\"physical activity\", \"breast cancer\", \"cervical cancer\", \"ovarian cancer\", \"endometrial cancer\"]"
        },
        {
          "criterion": "Treatment Line",
          "status": "PASS",
          "confidence": 0.8,
          "notes": "Line match assumed (not explicitly excluded)"
        },
        {
          "criterion": "Biomarker Requirements",
          "status": "PASS",
          "confidence": 1.0,
          "notes": "No biomarker requirements",
          "pending_tests": []
        },
        {
          "criterion": "Location (NYC Metro)",
          "status": "PASS",
          "confidence": 0.5,
          "notes": "No location data (assume match)"
        },
        {
          "criterion": "Inclusion Criteria (Full Text Available)",
          "status": "REVIEW",
          "confidence": 0.8,
          "notes": "See full text: * Lives on Oahu\n* Diagnosed with primary breast,cervical, endometrial or ovarian cancer (stage I-III)\n* Completed initial regional and systemic treatment for breast cancer 2 months ago\n* Physically ca..."
        },
        {
          "criterion": "Exclusion Criteria (Full Text Available)",
          "status": "REVIEW",
          "confidence": 0.8,
          "notes": "See full text: * Currently undergoing chemotherapy or radiation therapy..."
        }
      ],
      "summary": "4/6 criteria met"
    },
    "3_strategic_scenarios": {
      "best_case": {
        "probability": 0.6666666666666666,
        "scenario": "All pending biomarker tests return favorable results",
        "eligibility": "HIGH"
      },
      "most_likely": {
        "probability": 0.6666666666666666,
        "scenario": "50% of pending tests pass, some may require additional screening",
        "eligibility": "MODERATE"
      },
      "challenge": {
        "probability": 0.6666666666666666,
        "scenario": "Some pending tests fail, may need alternative trials",
        "eligibility": "LOW"
      }
    },
    "4_tactical_recommendations": [
      {
        "action": "Proceed with trial enrollment",
        "lab": "N/A",
        "cost": "N/A",
        "timeline": "Immediate",
        "priority": "HIGH",
        "rationale": "All eligibility criteria met"
      }
    ],
    "5_drug_mechanisms": {
      "[": {
        "mechanism": "[NEEDS VERIFICATION] Mechanism not found in database for [",
        "layman": "[NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.",
        "evidence_tier": "UNKNOWN"
      },
      "\"": {
        "mechanism": "[NEEDS VERIFICATION] Mechanism not found in database for \"",
        "layman": "[NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.",
        "evidence_tier": "UNKNOWN"
      },
      "H": {
        "mechanism": "Alkylating agent. Forms DNA cross-links, causing apoptosis.",
        "layman": "A chemotherapy drug that damages cancer cell DNA.",
        "evidence_tier": "STANDARD"
      },
      "u": {
        "mechanism": "Anti-VEGF monoclonal antibody. Blocks vascular endothelial growth factor, inhibiting angiogenesis.",
        "layman": "A targeted therapy that starves tumors by cutting off their blood supply.",
        "evidence_tier": "SUPPORTED"
      },
      "l": {
        "mechanism": "Platinum-based alkylating agent. Forms DNA cross-links, causing double-strand breaks and apoptosis.",
        "layman": "A chemotherapy drug that damages cancer cell DNA, preventing cell division.",
        "evidence_tier": "STANDARD"
      },
      "a": {
        "mechanism": "Platinum-based alkylating agent. Forms DNA cross-links, causing double-strand breaks and apoptosis.",
        "layman": "A chemotherapy drug that damages cancer cell DNA, preventing cell division.",
        "evidence_tier": "STANDARD"
      },
      "]": {
        "mechanism": "[NEEDS VERIFICATION] Mechanism not found in database for ]",
        "layman": "[NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.",
        "evidence_tier": "UNKNOWN"
      }
    },
    "6_location_details": [],
    "7_timeline": {
      "study_start": "",
      "primary_completion": ""
    },
    "8_full_eligibility_text": {
      "inclusion_criteria": "* Lives on Oahu\n* Diagnosed with primary breast,cervical, endometrial or ovarian cancer (stage I-III)\n* Completed initial regional and systemic treatment for breast cancer 2 months ago\n* Physically capable of doing the hula-based physical activity\n* Receives approval by attending physician to participate in trial",
      "exclusion_criteria": "* Currently undergoing chemotherapy or radiation therapy"
    },
    "9_contact_information": [],
    "10_provenance": {
      "generated_by": "JR2",
      "data_sources": [
        "SQLite",
        "Diffbot",
        "DRUG_MECHANISM_DB"
      ],
      "confidence_flags": [
        "[INFERRED]",
        "[NEEDS VERIFICATION]"
      ]
    }
  }
}